These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 2995565)
1. Conditions for haemolysis by flaviviruses and characterization of the haemolysin. Cammack N; Gould EA J Gen Virol; 1985 Oct; 66 ( Pt 10)():2291-6. PubMed ID: 2995565 [TBL] [Abstract][Full Text] [Related]
2. Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies. Gould EA; Buckley A; Cammack N; Barrett AD; Clegg JC; Ishak R; Varma MG J Gen Virol; 1985 Jul; 66 ( Pt 7)():1369-82. PubMed ID: 2410549 [TBL] [Abstract][Full Text] [Related]
3. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585 [TBL] [Abstract][Full Text] [Related]
4. Antigenic comparison of envelope protein E between Japanese encephalitis virus and some other flaviviruses using monoclonal antibodies. Kimura-Kuroda J; Yasui K J Gen Virol; 1986 Dec; 67 ( Pt 12)():2663-72. PubMed ID: 2432163 [TBL] [Abstract][Full Text] [Related]
5. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. Kayser M; Klein H; Paasch I; Pilaski J; Blenk H; Heeg K J Med Virol; 1985 Sep; 17(1):35-45. PubMed ID: 2995571 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547 [TBL] [Abstract][Full Text] [Related]
7. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus. Barrett AD; Mathews JH; Miller BR; Medlen AR; Ledger TN; Roehrig JT J Gen Virol; 1990 Jan; 71 ( Pt 1)():13-8. PubMed ID: 1689367 [TBL] [Abstract][Full Text] [Related]
8. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. Schlesinger JJ; Brandriss MW; Walsh EE J Immunol; 1985 Oct; 135(4):2805-9. PubMed ID: 4031501 [TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029 [TBL] [Abstract][Full Text] [Related]
10. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. Schlesinger JJ; Walsh EE; Brandriss MW J Gen Virol; 1984 Oct; 65 ( Pt 10)():1637-44. PubMed ID: 6208313 [TBL] [Abstract][Full Text] [Related]
11. Survival of mice immunized with monoclonal antibodies against glycoprotein E of Japanese encephalitis virus before or after infection with Japanese encephalitis, West Nile, and Dengue viruses. Gupta AK; Lad VJ; Koshy AA Acta Virol; 2008; 52(4):219-24. PubMed ID: 19143477 [TBL] [Abstract][Full Text] [Related]
12. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690 [TBL] [Abstract][Full Text] [Related]
13. Neutralization of yellow fever virus studied using monoclonal and polyclonal antibodies. Buckley A; Gould EA J Gen Virol; 1985 Dec; 66 ( Pt 12)():2523-31. PubMed ID: 2999305 [TBL] [Abstract][Full Text] [Related]
14. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus. Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387 [TBL] [Abstract][Full Text] [Related]
15. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. Schlesinger JJ; Chapman S J Gen Virol; 1995 Jan; 76 ( Pt 1)():217-20. PubMed ID: 7844536 [TBL] [Abstract][Full Text] [Related]
16. Effects of low pH on hemagglutinating and hemolytic activities of west equine encephalomyelitis virus. Villela MT; Couceiro JN; Cabral MC Braz J Med Biol Res; 1994 Mar; 27(3):613-21. PubMed ID: 8081285 [TBL] [Abstract][Full Text] [Related]
17. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893 [TBL] [Abstract][Full Text] [Related]
18. [Monoclonal antibodies to flavivirus antigens induced by a vaccinal strain of yellow fever]. Gaĭdamovich SIa; Mel'nikova EE; Mikheeva TG; Shutkova TM; Sveshnikova NA Vopr Virusol; 1988; 33(4):461-5. PubMed ID: 2848367 [TBL] [Abstract][Full Text] [Related]
19. Interferon induction by flavi- and orbiviruses in L-M cell line. Kedarnath N; Cecilia D; Gore MM; Banerjea AC; Ghosh SN Acta Virol; 1983 Jan; 27(1):80-2. PubMed ID: 6133435 [TBL] [Abstract][Full Text] [Related]
20. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. Gould EA; Buckley A; Cane PA; Higgs S; Cammack N J Gen Virol; 1989 Jul; 70 ( Pt 7)():1889-94. PubMed ID: 2472467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]